Biomedical subjects

M Terashima

Publications and source records attributed to M Terashima.

279 records · Page 16Linked to original sources

PubMedDate not supplied

Breast-conservation treatment for patients with ductal carcinoma in situ.

Fourteen cases with symptomatic ductal carcinoma in situ (DCIS) were treated with breast-conservation treatment intensified with endocrine therapy. Nine of 14 patients with palpable mass had tumor detected on mammography. CT, ultrasonography, and MRI were able to detect linear and/or spotty lesion or enhancement suggesting DCIS. Whereas these findings were not particular to DCIS, the combination of these modalities would be useful in deciding the extent of resection for DCIS. There was no patient selection for breast-conservation treatment in our department. All patients received tangential and boost radiation, and were treated with endocrine therapy using anti-estrogen drugs. The reason that nine cases had close margins (<5 mm) might be on account of the treatment including lumpectomy with 1 cm of surgical margin. In spite of their margin status, no local or systemic failure was experienced, and the cosmetic results of most patients were rated as excellent or good. Therefore, our breast-conservation treatment intensified with systemic therapy is thought to be adequate for patients with symptomatic DCIS. Six of eight cases who received preoperative treatment containing endocrine therapy with or without CAF chemotherapy showed a decrease in tumor size. Preoperative treatment may effect the microinvasion and/or breast tissue surrounding a DCIS tumor.

Adult↗

PubMedDate not supplied

Telomerase assay as a possible predictor of the response to anticancer chemotherapy.

BACKGROUND: The correlation between telomerase activity and antitumor effects was investigated in cell lines of human gastric (MKN-28, MKN-45, and MKN-74) and breast (T-47D, MCF-7, ZR75-1) cancers to evaluate the possibility of utilizing this enzyme to predict tumor response to chemotherapy. MATERIALS AND METHODS: After culture with various concentrations of 5-fluorouracil (5-FU) or doxorubicin (DOX) for 3 days, cell viability (trypan blue exclusion), cell cycle distribution (flow cytometry), and telomerase (TRAP-EZE) were measured. RESULTS: Telomerase activity correlated significantly with the number of viable cells. After drug exposure, this activity decreased rapidly in a dose-dependent fashion in most cell lines. There was no correlation between telomerase activity and the distribution of cells in the cell cycle. CONCLUSIONS: As the assay for telomerase activity is extremely sensitive and is virtually specific to cancer cells, this method may prove useful for the sensitivity testing of small specimens of human tumors.

Adenocarcinoma↗

PubMedDate not supplied

Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.

BACKGROUND: The role of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) enzyme activities in tumor progression and sensitivity to 5-fluorouracil (5-FU) were evaluated. MATERIALS AND METHODS: TS and DPD activities were measured in 81 clinical samples of gastric cancer. TS and DPD activities were determined by 5-fluorodeoxyuridine monophosphate binding assay and by radioenzymatic assay, respectively. Sensitivity to 5-FU was determined by in vitro ATP assay. RESULTS: There was no correlation between TS activity and sensitivity to 5-FU. However, a weak correlation was found between DPD activity and sensitivity to 5-FU. In a subgroup of patients who did not receive adjuvant chemotherapy, overall survival was poorer in patients with high TS activity (p=0.0265). Conversely, in a subgroup of patients who received 5-FU-based adjuvant chemotherapy, overall survival was poorer in patients with high DPD activity (p=0.0465). CONCLUSION: These results suggest that TS has an important role in tumor progression and DPD may be the dominant predictor of 5-FU sensitivity in gastric cancer.

Adult↗

PubMedDate not supplied

The effects of immune globulin on endotoxemia.

Ten patients (mean age, 40 years; 2 women) with endotoxemia received 2.5 gm of immune globulin daily for 4 days or 5 gm daily for 2 days. In all patients, plasma endotoxin levels decreased to normal levels (< or = 9.8 pg/ml) within a mean of 3.2 days after starting immune globulin treatment, and body temperatures decreased to < 37 degrees C within 4.5 days. In 10 antibiotic-treated (control) patients with endotoxemia who did not receive immune globulin, plasma endotoxin levels declined to normal levels in 6 and their body temperatures dropped to normal levels within 5.0 days; no changes in body temperature were noted in the 4 patients whose plasma endotoxin levels did not decrease.

Adult↗

PubMedDate not supplied

Treatment of endotoxemia with low-dose intramuscular injections or oral administration of polymyxin B.

Thirty patients with sepsis received 50,000 U of polymyxin B intramuscularly per day (n = 22) or 3 million U orally per day (n = 8). Plasma endotoxin levels were measured by the Endospecy test after treating the plasma with a new perchloric acid method. Plasma endotoxin levels were reduced to normal values (less than 9.8 pg/ml) in all the injected patients within two days and in all the orally treated patients within three days. Clinical symptoms were also ameliorated. No treatment side effects were reported. It is concluded that polymyxin B is a safe and effective treatment against endotoxemia.

Administration, Oral↗

PubMedDate not supplied

A new surgical technique for treatment of annuloaortic ectasia.

Five patients with far advanced cystic medial necrosis of the ascending aorta associated with aortic regurgitation were operated upon using a method not previously described. This new method consists of a special wrapping procedure which acts like a tubular prosthesis replacement and a new technique of fixation of aortic valve prosthesis in order to prevent periprosthetic leakage. The advantages of this new alternative method comparing to the procedure of Bentall and DeBono are discussed.

Adolescent↗

PubMedDate not supplied

Early experiences of breast-conservation treatment combined with tamoxifen and CAF chemotherapy for breast cancer of stages I and II.

A total of 39 patients with breast cancer of stages I and II received breast-conservation treatment (BCT) combined with tamoxifen and systemic chemotherapy (CAF) from August 1989 to March 1993. All of these patients visited the outpatient clinic of the Department of Radiology of Kochi Medical School Hospital, with an obvious desire to undertake BCT. During this period, another two patients with the same desire were treated with modified radical mastectomy, because of obviously positive surgical margins in frozen sections obtained at surgery. The percentage of patients treated by BCT was, therefore, 95.1%. All of the patients were females, and their average age was 49.9 years. Thirty-six of these 39 patients underwent lumpectomy, and another three patients with large-sized tumor or suspected extensive intraductal component underwent quadrantectomy or wide local excision. Nineteen of these 39 patients who were over 70 years old or had no clinically detectable axillary lymph node swelling received tangential field radiotherapy to their ipsilateral axillary region instead of axillary dissection. At the end of May 1993, the mean follow-up time was 22.4 months. Until now, one patient (T2N1M0, stage IIB) has died of distant metastases of breast cancer to bone, liver, lung, and brain, and another patient, aged 81, died of pneumonia with no evidence of breast cancer progression. The overall survival rates were, therefore, 100% (30/30), 90.0% (18/20), and 75.0% (6/8) at 1 year, 2 years, and 3 years, respectively. Cause-specific survival rates were 100% (30/30), 94.7% (18/19), and 85.7% (6/7) at 1, 2, and 3 years, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

PubMedDate not supplied

A surgical treatment with an "on-lay" patch for experimental myocardial infarction.

The authors proposed a new operative method for acute myocardial infarction with a prosthetic "on-lay" patch in a dog model, and functional and morphological studies were made in the acute and long survival dogs. In this method, the following advantages were observed: Improvement of cardiac functions, reduction of mortality, prevention of ventricular aneurysm, prevention of the occurrence of arrhythmias and ventricular fibrillation, minimum reduction of the intracardiac capacity and no suture dehiscence resulting in cardiac rupture. It is shown that this surgical method can be applied securely to the emergent cases of acute myocardial infarction failing to respond to medical therapy.

Acute Disease↗

PubMedDate not supplied

CD34-positive cell yield in peripheral blood of cancer patients during radiation therapy.

For the purpose of evaluating the feasibility of inducing CD34-positive cells in peripheral blood by radiation therapy, we examined the changes in CD34-positive cells in 21 cancer patients (16 with lung cancer and five with esophageal cancer) during thoracic radiotherapy using flow cytometry and CD34 monoclonal antibody. Although assays of granulocyte-colony-forming units (G-CFU) and granulocyte-monocyte-colony-forming units (GM-CFU) were also performed for 16 of the patients during radiation therapy, in most of these cases there was approximately one G-CFU or GM-CFU for every 100 CD34-positive cells. Seven of the 21 cancer patients showed percentages of CD34-positive cells of more than 3% (more than mean + 2 S.D.; standard deviation) of mononuclear cells in peripheral blood in at least one of the examinations. However, six of these seven patients were in stage IV with distant metastases (four with lung cancer and two with esophageal cancer), and another lung cancer patient was in stage III. Therefore, CD-34 positive cells were shown to appear in peripheral blood especially in the patients with advanced stages of malignancy, and further examinations are needed to induce CD34-positive cells by radiation therapy for possible application of ultra-high dose chemotherapy supported by peripheral blood stem cell transplantation.

Antigens, CD34↗